CA2720523C - Treatment of bladder dysfunction using liposomal botulinum toxin - Google Patents

Treatment of bladder dysfunction using liposomal botulinum toxin Download PDF

Info

Publication number
CA2720523C
CA2720523C CA2720523A CA2720523A CA2720523C CA 2720523 C CA2720523 C CA 2720523C CA 2720523 A CA2720523 A CA 2720523A CA 2720523 A CA2720523 A CA 2720523A CA 2720523 C CA2720523 C CA 2720523C
Authority
CA
Canada
Prior art keywords
bont
bladder
botulinum toxin
instillation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2720523A
Other languages
English (en)
French (fr)
Other versions
CA2720523A1 (en
Inventor
Michael B. Chancellor
Jonathan H. Kaufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipella Pharmaceuticals Inc
Original Assignee
Lipella Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipella Pharmaceuticals Inc filed Critical Lipella Pharmaceuticals Inc
Publication of CA2720523A1 publication Critical patent/CA2720523A1/en
Application granted granted Critical
Publication of CA2720523C publication Critical patent/CA2720523C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2720523A 2008-04-04 2009-04-03 Treatment of bladder dysfunction using liposomal botulinum toxin Expired - Fee Related CA2720523C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4253608P 2008-04-04 2008-04-04
US61/042,536 2008-04-04
US11026608P 2008-10-31 2008-10-31
US61/110,266 2008-10-31
PCT/US2009/039489 WO2009139984A2 (en) 2008-04-04 2009-04-03 Method of treatment for bladder dysfunction

Publications (2)

Publication Number Publication Date
CA2720523A1 CA2720523A1 (en) 2009-11-19
CA2720523C true CA2720523C (en) 2013-12-17

Family

ID=41319235

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2720523A Expired - Fee Related CA2720523C (en) 2008-04-04 2009-04-03 Treatment of bladder dysfunction using liposomal botulinum toxin

Country Status (10)

Country Link
US (1) US20120093920A1 (enExample)
EP (2) EP2273976A2 (enExample)
JP (2) JP5538359B2 (enExample)
KR (1) KR20100131471A (enExample)
CN (1) CN102065841A (enExample)
AU (1) AU2009246834B2 (enExample)
BR (1) BRPI0911098A2 (enExample)
CA (1) CA2720523C (enExample)
MX (1) MX2010010635A (enExample)
WO (1) WO2009139984A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
RU2657591C2 (ru) 2012-08-31 2018-06-14 ТАРИС Биомедикал ЛЛК Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения
KR102383496B1 (ko) 2012-08-31 2022-04-08 타리스 바이오메디컬 엘엘씨 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
CA2927356C (en) 2013-10-22 2022-08-23 Lipella Pharmaceuticals Inc. Delivery of agents using metastable liposomes
US20160045623A1 (en) 2015-04-03 2016-02-18 Lipella Pharmaceuticals, Inc. Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)
WO2019023388A1 (en) 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
PE20210041A1 (es) 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
KR102398743B1 (ko) * 2020-09-03 2022-05-16 충남대학교병원 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물
TWI760996B (zh) * 2020-12-25 2022-04-11 姜秉均 含有疏水性物質的奈米組成物及其製備方法與用途
CN117883383A (zh) * 2023-12-26 2024-04-16 中国康复研究中心 一种作为A型肉毒素载体的TiO2纳米粒子及制备方法
US12272439B1 (en) 2024-05-06 2025-04-08 Immunitybio, Inc. Distributed ledger for medicament administration tracking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
AU2003259246A1 (en) 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
EP1933813A4 (en) * 2005-10-11 2013-02-27 Univ Pittsburgh SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER

Also Published As

Publication number Publication date
MX2010010635A (es) 2010-12-17
AU2009246834B2 (en) 2012-12-06
US20120093920A1 (en) 2012-04-19
CA2720523A1 (en) 2009-11-19
JP5538359B2 (ja) 2014-07-02
KR20100131471A (ko) 2010-12-15
BRPI0911098A2 (pt) 2015-10-06
EP2599476A1 (en) 2013-06-05
AU2009246834A1 (en) 2009-11-19
JP2014062125A (ja) 2014-04-10
EP2273976A2 (en) 2011-01-19
WO2009139984A2 (en) 2009-11-19
WO2009139984A3 (en) 2010-03-04
CN102065841A (zh) 2011-05-18
JP2011516497A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
CA2720523C (en) Treatment of bladder dysfunction using liposomal botulinum toxin
Chancellor et al. Treatment of interstitial cystitis
Fraser et al. Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat
ES2822942T3 (es) Formulaciones de productos biológicos para instilación intravesical
Wang et al. A novel hydrogel-based combination therapy for effective neuroregeneration after spinal cord injury
Windsor et al. Metabolic management of severe acute pancreatitis
ES2821731T3 (es) Formulaciones de productos biológicos para instilación intravesical
US20120301540A1 (en) Method of treatment for bladder dysfunction
Zhang et al. Inhalation of taraxasterol loaded mixed micelles for the treatment of idiopathic pulmonary fibrosis
Zhang et al. An injectable thermosensitive hyaluronic acid/pluronic F-127 hydrogel for deep penetration and combination therapy of frozen shoulder
He et al. Targeted-lung delivery of bardoxolone methyl using PECAM-1 antibody-conjugated nanostructure lipid carriers for the treatment of lung inflammation
RU2527679C2 (ru) Терапевтическое средство для лечения заболевания нижних мочевых путей и средство для улучшения симптома нижних мочевых путей
US20160331683A1 (en) Water-in-oil type emulsion for treating a disease of the eye
RU2741966C2 (ru) Усовершенствованная схема инъекции в мочевой пузырь для введения ботулотоксинов
Kaufman et al. State of the art in intravesical therapy for lower urinary tract symptoms
CN103784942B (zh) 青蒿琥酯与乌司他丁联合治疗胰腺炎的用途
Liu et al. Nano-BTA: a new strategy for Intravesical delivery of botulinum toxin a
Hung et al. Role of liposome in treatment of overactive bladder and interstitial cystitis
CN105342984A (zh) 一种用于治疗急性胰腺炎的可注射温敏凝胶制剂
US8283323B2 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
KR102398743B1 (ko) 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물
US9636299B2 (en) Method for treating diabetic retinopathy
US20240115503A1 (en) Intravesical delivery of hydrophilic therapeutic agents using liposomes
CN100364610C (zh) 提高蚓激酶口服吸收生物利用度的方法
Asif et al. Interstitial Cystitis-Critical Assessment of Current Treatment and Opportunities for Nanodelivery

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160404